ESCMID* guideline for the diagnosis and management of Candida diseases 2012: patients with HIV infection or AIDS

被引：62

作者：

Lortholary, O. ^{[1
,2
]}

Petrikkos, G. ^{[3
]}

Akova, M. ^{[4
]}

Arendrup, M. C. ^{[5
]}

Arikan-Akdagli, S. ^{[6
]}

Bassetti, M. ^{[7
]}

Bille, J.

Calandra, T. ^{[8
,9
]}

Castagnola, E. ^{[10
]}

Cornely, O. A. ^{[11
]}

Cuenca-Estrella, M. ^{[12
]}

Donnelly, J. P. ^{[13
]}

Garbino, J. ^{[14
]}

Groll, A. H. ^{[15
]}

Herbrecht, R. ^{[16
]}

Hope, W. W. ^{[17
]}

Jensen, H. E. ^{[18
]}

Kullberg, B. J. ^{[13
]}

Lass-Floerl, C. ^{[19
]}

Meersseman, W. ^{[20
]}

Richardson, M. D. ^{[21
,22
]}

Roilides, E. ^{[23
,24
]}

Verweij, P. E. ^{[13
]}

Viscoli, C. ^{[25
]}

Ullmann, A. J. ^{[26
]}

机构：

[1] Univ Paris 05, Hop Necker Enfants Malad, APHP,Serv Malad Infect & Trop, Ctr Infectiol Necker Pasteur,IHU Imagine, F-75743 Paris 15, France

[2] Inst Pasteur, CNRS, URA3012,Unite Mycol Mol, Ctr Natl Reference Mycoses Invas & Antifong, Paris, France

[3] Univ Athens, Sch Med, Dept Internal Med 4, ATTIKON Hosp,RIMINI Haidari 1, Athens 11528, Greece

[4] Hacettepe Univ, Sch Med, Dept Med, Ankara, Turkey

[5] Statens Serum Inst, DK-2300 Copenhagen, Denmark

[6] Hacettepe Univ, Sch Med, Dept Med Microbiol, Ankara, Turkey

[7] Santa Maria Misericordia Univ Hosp, Udine, Italy

[8] CHU Vaudois, Dept Med, Infect Dis Serv, CH-1011 Lausanne, Switzerland

[9] Univ Lausanne, Lausanne, Switzerland

[10] Childrens Hosp, Inst Giannina Gaslini, Genoa, Italy

[11] Univ Cologne, Dept Internal Med 1,German Ctr Infect Res, Clin Trials Ctr Cologne,ZKS Koln,BMBF 01KN1106, Ctr Integrated Oncol CIO KolnBonn,Cologne Excelle, D-50931 Cologne, Germany

[12] Inst Salud Carlos III, Ctr Nacl Microbiol, Madrid, Spain

[13] Radboud Univ Nijmegen, Med Ctr, NL-6525 ED Nijmegen, Netherlands

[14] Univ Hosp Geneva, Geneva, Switzerland

[15] Univ Childrens Hosp, Ctr Bone Marrow Transplantat, Dept Pediat Hematol Oncol, Munster, Germany

[16] Univ Strasbourg, Hop Hautepierre, Strasbourg, France

[17] Univ Liverpool, Dept Mol & Clin Pharmacol, Liverpool L69 3BX, Merseyside, England

[18] Univ Copenhagen, Frederiksberg, Denmark

[19] Innsbruck Med Univ, Div Hyg & Med Microbiol, Innsbruck, Austria

[20] Univ Hosp Gasthuisberg, B-3000 Louvain, Belgium

[21] Univ S Manchester Hosp, Mycol Reference Ctr, Manchester M20 8LR, Lancs, England

[22] Univ Manchester, Manchester Acad Hlth Sci Ctr, Manchester, Lancs, England

[23] Aristotle Univ Thessaloniki, Sch Med, Dept Pediat 3, GR-54006 Thessaloniki, Greece

[24] Hippokrateion Hosp, Thessaloniki, Greece

[25] Univ Genoa, IRCCS San Martino IST, Genoa, Italy

[26] Univ Wurzburg, Dept Internal Med 2, D-97080 Wurzburg, Germany

来源：

CLINICAL MICROBIOLOGY AND INFECTION | 2012年 / 18卷

基金：

英国医学研究理事会;

关键词：

Candidiasis; Europe; guideline; HIV AIDS; HUMAN-IMMUNODEFICIENCY-VIRUS; ITRACONAZOLE ORAL SOLUTION; REFRACTORY OROPHARYNGEAL CANDIDIASIS; FLUCONAZOLE-RESISTANT CANDIDA; DOUBLE-BLIND; ESOPHAGEAL CANDIDIASIS; IN-VITRO; CLOTRIMAZOLE TROCHES; MUCOSAL CANDIDIASIS; FUNGAL-INFECTIONS;

D O I：

10.1111/1469-0691.12042

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

Clin Microbiol Infect 2012; 18 (Suppl. 7): 6877 Abstract Mucosal candidiasis is frequent in immunocompromised HIV-infected highly active antiretroviral (HAART) naive patients or those who have failed therapy. Mucosal candidiasis is a marker of progressive immune deficiency. Because of the frequently marked and prompt immune reconstitution induced by HAART, there is no recommendation for primary antifungal prophylaxis of mucosal candidiasis in the HIV setting in Europe, although it has been evidenced as effective in the pre-HAART era. Fluconazole remains the first line of therapy for both oropharyngeal candidiasis and oesophageal candidiasis and should be preferred to itraconazole oral solution (or capsules when not available) due to fewer side effects. For patients who still present with fluconazole-refractory mucosal candidiasis, oral treatment with any other azole should be preferred based on precise Candida species identification and susceptibility testing results in addition to the optimization of HAART when feasible. For vaginal candidiasis, topical therapy is preferred.

引用

页码：68 / 77

页数：10

共 84 条

[1] A randomized, double-blind, double-dummy, multicenter trial of voriconazole and fluconazole in the treatment of esophageal candidiasis in immunocompromised patients [J].